Lipocine Inc (LPCN) FinancialsLPCNLipocine Inc

Evaluating the bottom line, Lipocine Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1495.14%, while the net margin is -1379.59%. These profitability ratios, combined with a Return on Equity (ROE) of -60.94%, provide a clear picture of how effectively LPCN converts its operational activities into shareholder value.

In the context of the broader market, LPCN competes directly with industry leaders such as CYCN and RKTO. With a market capitalization of $17.40M, it holds a significant position in the sector. When comparing efficiency, LPCN's gross margin of N/A stands against CYCN's N/A and RKTO's N/A. Such benchmarking helps identify whether Lipocine Inc is trading at a premium or discount relative to its financial performance.

Lipocine reported a total revenue of $1.97 million for FY 2026, which is significantly below industry expectations. The company has been experiencing substantial net losses, with a GAAP EPS of -$1.69 for FY 2026, indicating challenges in achieving profitability.